{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T20:54:18Z","timestamp":1762376058064},"reference-count":74,"publisher":"Public Library of Science (PLoS)","issue":"2","license":[{"start":{"date-parts":[[2016,2,4]],"date-time":"2016-02-04T00:00:00Z","timestamp":1454544000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0148101","type":"journal-article","created":{"date-parts":[[2016,2,4]],"date-time":"2016-02-04T18:38:37Z","timestamp":1454611117000},"page":"e0148101","update-policy":"http:\/\/dx.doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":22,"title":["Expression and Prognostic Significance of Human Epidermal Growth Factor Receptors 1 and 3 in Gastric and Esophageal Adenocarcinoma"],"prefix":"10.1371","volume":"11","author":[{"given":"Charlotta","family":"Hedner","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Borg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bj\u00f6rn","family":"Nodin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emelie","family":"Karnevi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karin","family":"Jirstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jakob","family":"Eberhard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2016,2,4]]},"reference":[{"key":"ref1","article-title":"Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012","author":"J Ferlay","year":"2014","journal-title":"International journal of cancer Journal international du cancer"},{"issue":"5","key":"ref2","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1002\/ijc.23232","article-title":"Trends in oesophageal cancer incidence and mortality in Europe","volume":"122","author":"C Bosetti","year":"2008","journal-title":"International journal of cancer Journal international du cancer"},{"key":"ref3","article-title":"Global Cancer Facts &amp; Figures","year":"2011"},{"key":"ref4","first-page":"563","article-title":"Surgical Pathology of the GI Tract, Liver, Biliary Tract and Pancreas: Expert Consult\u2014Online and Print. 1","author":"GY Lauwers","year":"2009"},{"issue":"10","key":"ref5","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1002\/(SICI)1097-0142(19981115)83:10<2049::AID-CNCR1>3.0.CO;2-2","article-title":"Changing patterns in the incidence of esophageal and gastric carcinoma in the United States","volume":"83","author":"SS Devesa","year":"1998","journal-title":"Cancer"},{"issue":"1","key":"ref6","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.semradonc.2012.09.008","article-title":"Epidemiology and risk factors for gastroesophageal junction tumors: understanding the rising incidence of this disease","volume":"23","author":"MF Buas","year":"2013","journal-title":"Seminars in radiation oncology"},{"issue":"1","key":"ref7","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa055531","article-title":"Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer","volume":"355","author":"D Cunningham","year":"2006","journal-title":"The New England journal of medicine"},{"issue":"22","key":"ref8","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1056\/NEJMoa1112088","article-title":"Preoperative chemoradiotherapy for esophageal or junctional cancer","volume":"366","author":"P van Hagen","year":"2012","journal-title":"The New England journal of medicine"},{"issue":"9742","key":"ref9","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","article-title":"Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial","volume":"376","author":"YJ Bang","year":"2010","journal-title":"Lancet"},{"issue":"7","key":"ref10","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1016\/j.ejca.2012.12.016","article-title":"Role of chemotherapy for advanced\/recurrent gastric cancer: an individual-patient-data meta-analysis","volume":"49","author":"G Group","year":"2013","journal-title":"European journal of cancer"},{"issue":"4","key":"ref11","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/sj.bjc.6603910","article-title":"Targeting HER proteins in cancer therapy and the role of the non-target HER3","volume":"97","author":"AC Hsieh","year":"2007","journal-title":"British journal of cancer"},{"issue":"9","key":"ref12","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1016\/j.semcdb.2010.08.007","article-title":"The role of HER3, the unpretentious member of the HER family, in cancer biology and cancer therapeutics","volume":"21","author":"DN Amin","year":"2010","journal-title":"Seminars in cell & developmental biology"},{"issue":"3","key":"ref13","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1517\/13543784.2013.761972","article-title":"Investigational therapies targeting the ErbB (EGFR, HER2, HER3, HER4) family in GI cancers","volume":"22","author":"MD Desai","year":"2013","journal-title":"Expert opinion on investigational drugs"},{"issue":"8","key":"ref14","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/nrc3309","article-title":"The ERBB network: at last, cancer therapy meets systems biology","volume":"12","author":"Y Yarden","year":"2012","journal-title":"Nature reviews Cancer"},{"issue":"21","key":"ref15","doi-asserted-by":"crossref","first-page":"10222","DOI":"10.18632\/oncotarget.2655","article-title":"Regulation of ERBB3\/HER3 signaling in cancer","volume":"5","author":"K Mujoo","year":"2014","journal-title":"Oncotarget"},{"issue":"5","key":"ref16","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/nrc1609","article-title":"ERBB receptors and cancer: the complexity of targeted inhibitors","volume":"5","author":"NE Hynes","year":"2005","journal-title":"Nature reviews Cancer"},{"issue":"4","key":"ref17","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1093\/jnci\/djs501","article-title":"HER3 overexpression and survival in solid tumors: a meta-analysis","volume":"105","author":"A Ocana","year":"2013","journal-title":"Journal of the National Cancer Institute"},{"issue":"2","key":"ref18","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/35052073","article-title":"Untangling the ErbB signalling network","volume":"2","author":"Y Yarden","year":"2001","journal-title":"Nature reviews Molecular cell biology"},{"issue":"23","key":"ref19","doi-asserted-by":"crossref","first-page":"7843","DOI":"10.1158\/1078-0432.CCR-08-1064","article-title":"High expression of HER3 is associated with a decreased survival in gastric cancer","volume":"14","author":"M Hayashi","year":"2008","journal-title":"Clinical cancer research: an official journal of the American Association for Cancer Research"},{"issue":"5","key":"ref20","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.arcmed.2013.07.001","article-title":"Prognostic role of human epidermal growth factor receptor in gastric cancer: a systematic review and meta-analysis","volume":"44","author":"C Chen","year":"2013","journal-title":"Archives of medical research"},{"issue":"6","key":"ref21","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1111\/j.1365-2559.2008.03021.x","article-title":"EGFR in gastric carcinomas: prognostic significance of protein overexpression and high gene copy number","volume":"52","author":"MA Kim","year":"2008","journal-title":"Histopathology"},{"issue":"4","key":"ref22","doi-asserted-by":"crossref","first-page":"480","DOI":"10.3109\/0284186X.2014.983654","article-title":"HER3 expression in primary colorectal cancer including corresponding metastases in lymph node and liver","volume":"54","author":"F Ledel","year":"2015","journal-title":"Acta oncologica"},{"issue":"5","key":"ref23","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.ccr.2013.04.012","article-title":"Oncogenic ERBB3 mutations in human cancers","volume":"23","author":"BS Jaiswal","year":"2013","journal-title":"Cancer cell"},{"issue":"7126","key":"ref24","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/nature05474","article-title":"Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3","volume":"445","author":"NV Sergina","year":"2007","journal-title":"Nature"},{"issue":"5","key":"ref25","first-page":"1373","article-title":"HER3 comes of age: new insights into its functions and role in signaling, tumor biology, and cancer therapy. Clinical cancer research: an official journal of the","volume":"16","author":"MR Campbell","year":"2010","journal-title":"American Association for Cancer Research"},{"issue":"22","key":"ref26","doi-asserted-by":"crossref","first-page":"3030","DOI":"10.1200\/JCO.2010.33.6313","article-title":"Prognostic implications of altered human epidermal growth factor receptors (HERs) in gastric carcinomas: HER2 and HER3 are predictors of poor outcome","volume":"29","author":"MD Begnami","year":"2011","journal-title":"Journal of clinical oncology: official journal of the American Society of Clinical Oncology"},{"issue":"6","key":"ref27","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1038\/bjc.2011.280","article-title":"Phase II trial of modified FOLFOX6 and erlotinib in patients with metastatic or advanced adenocarcinoma of the oesophagus and gastro-oesophageal junction","volume":"105","author":"ZA Wainberg","year":"2011","journal-title":"British journal of cancer"},{"issue":"3","key":"ref28","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s00428-004-1048-7","article-title":"A proposal for diagnostically meaningful criteria to classify increased epidermal growth factor receptor and c-erbB-2 gene copy numbers in gastric carcinoma, based on correlation of fluorescence in situ hybridization and immunohistochemical measurements","volume":"445","author":"M Kimura","year":"2004","journal-title":"Virchows Archiv: an international journal of pathology"},{"issue":"21","key":"ref29","doi-asserted-by":"crossref","first-page":"5992","DOI":"10.1158\/1078-0432.CCR-12-1318","article-title":"Impact of expression of human epidermal growth factor receptors EGFR and ERBB2 on survival in stage II\/III gastric cancer","volume":"18","author":"M Terashima","year":"2012","journal-title":"Clinical cancer research: an official journal of the American Association for Cancer Research"},{"issue":"7","key":"ref30","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1002\/ijc.28771","article-title":"EGFR, HER2 and HER3 dimerization patterns guide targeted inhibition in two histotypes of esophageal cancer","volume":"135","author":"CD Fichter","year":"2014","journal-title":"International journal of cancer Journal international du cancer"},{"issue":"3","key":"ref31","first-page":"493","article-title":"EGFR, HER2 and HER3 expression in esophageal primary tumours and corresponding metastases","volume":"31","author":"Q Wei","year":"2007","journal-title":"International journal of oncology"},{"issue":"4","key":"ref32","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.gassur.2004.01.006","article-title":"Epidermal growth factor receptor expression correlates with histologic grade in resected esophageal adenocarcinoma","volume":"8","author":"NW Wilkinson","year":"2004","journal-title":"Journal of gastrointestinal surgery: official journal of the Society for Surgery of the Alimentary Tract"},{"issue":"17","key":"ref33","first-page":"6461","article-title":"Epidermal growth factor receptor, p53 mutation, and pathological response predict survival in patients with locally advanced esophageal cancer treated with preoperative chemoradiotherapy","volume":"9","author":"MK Gibson","year":"2003","journal-title":"Clinical cancer research: an official journal of the American Association for Cancer Research"},{"issue":"3","key":"ref34","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1002\/cncr.28435","article-title":"HER-2\/neu gene amplification in relation to expression of HER2 and HER3 proteins in patients with esophageal adenocarcinoma","volume":"120","author":"HH Yoon","year":"2014","journal-title":"Cancer"},{"issue":"4","key":"ref35","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1002\/cncr.22445","article-title":"Expression of epidermal growth factor receptor in esophageal and esophagogastric junction adenocarcinomas: association with poor outcome","volume":"109","author":"KL Wang","year":"2007","journal-title":"Cancer"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/2050-7771-2-11","article-title":"High expression of RNA-binding motif protein 3 in esophageal and gastric adenocarcinoma correlates with intestinal metaplasia-associated tumours and independently predicts a reduced risk of recurrence and death","volume":"2","author":"L Jonsson","year":"2014","journal-title":"Biomarker research"},{"issue":"1","key":"ref37","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/1479-5876-12-83","article-title":"Expression and prognostic significance of the polymeric immunoglobulin receptor in esophageal and gastric adenocarcinoma","volume":"12","author":"R Fristedt","year":"2014","journal-title":"J Transl Med"},{"key":"ref38","article-title":"SATB1 is an independent prognostic factor in radically resected upper gastrointestinal tract adenocarcinoma","author":"C Hedner","year":"2014","journal-title":"Virchows Arch"},{"issue":"7","key":"ref39","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1038\/nm0798-844","article-title":"Tissue microarrays for high-throughput molecular profiling of tumor specimens","volume":"4","author":"J Kononen","year":"1998","journal-title":"Nat Med"},{"issue":"5","key":"ref40","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1038\/modpathol.2011.198","article-title":"HER2 testing in gastric cancer: a practical approach","volume":"25","author":"J Ruschoff","year":"2012","journal-title":"Modern pathology: an official journal of the United States and Canadian Academy of Pathology, Inc."},{"key":"ref41","article-title":"Discordant human epidermal growth factor receptor 2 overexpression in primary and metastatic upper gastrointestinal adenocarcinoma signifies poor prognosis","author":"C Hedner","year":"2015","journal-title":"Histopathology"},{"issue":"10","key":"ref42","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1002\/j.1460-2075.1996.tb00603.x","article-title":"Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions","volume":"15","author":"R Pinkas-Kramarski","year":"1996","journal-title":"The EMBO journal"},{"issue":"5827","key":"ref43","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1126\/science.1141478","article-title":"MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling","volume":"316","author":"JA Engelman","year":"2007","journal-title":"Science"},{"issue":"6","key":"ref44","doi-asserted-by":"crossref","first-page":"3550","DOI":"10.1128\/MCB.14.6.3550","article-title":"ErbB3 is involved in activation of phosphatidylinositol 3-kinase by epidermal growth factor","volume":"14","author":"SP Soltoff","year":"1994","journal-title":"Molecular and cellular biology"},{"issue":"1","key":"ref45","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1128\/MCB.14.1.492","article-title":"Efficient coupling with phosphatidylinositol 3-kinase, but not phospholipase C gamma or GTPase-activating protein, distinguishes ErbB-3 signaling from that of other ErbB\/EGFR family members","volume":"14","author":"P Fedi","year":"1994","journal-title":"Molecular and cellular biology"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.advenzreg.2006.01.004","article-title":"Roles of the RAF\/MEK\/ERK and PI3K\/PTEN\/AKT pathways in malignant transformation and drug resistance","volume":"46","author":"JA McCubrey","year":"2006","journal-title":"Advances in enzyme regulation"},{"key":"ref47","article-title":"Molecular phenotypes of colorectal cancer and potential clinical applications","author":"JM Kocarnik","year":"2015","journal-title":"Gastroenterology report"},{"issue":"5","key":"ref48","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1634\/theoncologist.2014-0378","article-title":"Prospective comprehensive genomic profiling of advanced gastric carcinoma cases reveals frequent clinically relevant genomic alterations and new routes for targeted therapies","volume":"20","author":"SM Ali","year":"2015","journal-title":"The oncologist"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1186\/1756-0500-7-271","article-title":"Clinicopathological features and prognostic roles of KRAS, BRAF, PIK3CA and NRAS mutations in advanced gastric cancer","volume":"7","author":"N Takahashi","year":"2014","journal-title":"BMC research notes"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1186\/1471-2407-11-509","article-title":"Biomarker analysis of cetuximab plus oxaliplatin\/leucovorin\/5-fluorouracil in first-line metastatic gastric and oesophago-gastric junction cancer: results from a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO)","volume":"11","author":"B Luber","year":"2011","journal-title":"BMC cancer"},{"issue":"10","key":"ref51","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1200\/JCO.2005.03.4900","article-title":"Predictive factors for outcome in a phase II study of gefitinib in second-line treatment of advanced esophageal cancer patients","volume":"24","author":"ML Janmaat","year":"2006","journal-title":"Journal of clinical oncology: official journal of the American Society of Clinical Oncology"},{"issue":"30","key":"ref52","doi-asserted-by":"crossref","first-page":"4922","DOI":"10.1200\/JCO.2006.07.1316","article-title":"Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127","volume":"24","author":"T Dragovich","year":"2006","journal-title":"Journal of clinical oncology: official journal of the American Society of Clinical Oncology"},{"issue":"25","key":"ref53","doi-asserted-by":"crossref","first-page":"3945","DOI":"10.1200\/JCO.2010.29.2847","article-title":"Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for advanced esophagogastric cancer: dose-finding study for the prospective multicenter, randomized, phase II\/III REAL-3 trial","volume":"28","author":"AF Okines","year":"2010","journal-title":"Journal of clinical oncology: official journal of the American Society of Clinical Oncology"},{"issue":"11","key":"ref54","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1093\/annonc\/mdq247","article-title":"Matuzumab plus epirubicin, cisplatin and capecitabine (ECX) compared with epirubicin, cisplatin and capecitabine alone as first-line treatment in patients with advanced oesophago-gastric cancer: a randomised, multicentre open-label phase II study","volume":"21","author":"S Rao","year":"2010","journal-title":"Annals of oncology: official journal of the European Society for Medical Oncology \/ ESMO"},{"issue":"7","key":"ref55","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1158\/1535-7163.MCT-13-1093","article-title":"Combination of anti-HER3 antibody MM-121\/SAR256212 and cetuximab inhibits tumor growth in preclinical models of head and neck squamous cell carcinoma","volume":"13","author":"N Jiang","year":"2014","journal-title":"Molecular cancer therapeutics"},{"issue":"19","key":"ref56","doi-asserted-by":"crossref","first-page":"5869","DOI":"10.1158\/1078-0432.CCR-06-1970","article-title":"A phase II study of gefitinib monotherapy in advanced esophageal adenocarcinoma: evidence of gene expression, cellular, and clinical response","volume":"13","author":"DR Ferry","year":"2007","journal-title":"Clinical cancer research: an official journal of the American Association for Cancer Research"},{"issue":"8","key":"ref57","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1016\/S1470-2045(14)70024-5","article-title":"Gefitinib for oesophageal cancer progressing after chemotherapy (COG): a phase 3, multicentre, double-blind, placebo-controlled randomised trial","volume":"15","author":"SJ Dutton","year":"2014","journal-title":"The lancet oncology"},{"issue":"11","key":"ref58","doi-asserted-by":"crossref","first-page":"3078","DOI":"10.1158\/1078-0432.CCR-12-3051","article-title":"Phase I study of U3-1287, a fully human anti-HER3 monoclonal antibody, in patients with advanced solid tumors","volume":"19","author":"P LoRusso","year":"2013","journal-title":"Clinical cancer research: an official journal of the American Association for Cancer Research"},{"issue":"12","key":"ref59","doi-asserted-by":"crossref","first-page":"5021","DOI":"10.1073\/pnas.1016140108","article-title":"Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase","volume":"108","author":"JT Garrett","year":"2011","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"6","key":"ref60","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1007\/s00428-015-1747-2","article-title":"HER3 protein expression in relation to HER2 positivity in patients with primary colorectal cancer: clinical relevance and prognostic value","volume":"466","author":"AN Seo","year":"2015","journal-title":"Virchows Archiv: an international journal of pathology"},{"issue":"318","key":"ref61","doi-asserted-by":"crossref","first-page":"ra29","DOI":"10.1126\/scisignal.2005125","article-title":"Antagonism of EGFR and HER3 enhances the response to inhibitors of the PI3K-Akt pathway in triple-negative breast cancer","volume":"7","author":"JJ Tao","year":"2014","journal-title":"Science signaling"},{"key":"ref62","unstructured":"Petty R. <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/conference.ncri.org.uk\/epidermal-growth-factor-receptor-copy-number-gain-egfr-cng-and-response-to-gefitinib-in-oesophageal-cancer-oc-results-of-a-biomarker-analysis-of-a-phase-iii-trial-of-gefitinib-versus-placebo-tra\/\" xlink:type=\"simple\">http:\/\/conference.ncri.org.uk\/epidermal-growth-factor-receptor-copy-number-gain-egfr-cng-and-response-to-gefitinib-in-oesophageal-cancer-oc-results-of-a-biomarker-analysis-of-a-phase-iii-trial-of-gefitinib-versus-placebo-tra\/<\/ext-link> [2015-10-13]."},{"issue":"5","key":"ref63","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1038\/sj.bjc.6604936","article-title":"Biomarker analysis in stage III-IV (M0) gastric cancer patients who received curative surgery followed by adjuvant 5-fluorouracil and cisplatin chemotherapy: epidermal growth factor receptor (EGFR) associated with favourable survival","volume":"100","author":"JS Kim","year":"2009","journal-title":"British journal of cancer"},{"issue":"9","key":"ref64","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1007\/s00384-009-0702-6","article-title":"ErbB family immunohistochemical expression in colorectal cancer patients with higher risk of recurrence after radical surgery","volume":"24","author":"G Baiocchi","year":"2009","journal-title":"International journal of colorectal disease"},{"issue":"3","key":"ref65","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1111\/j.1365-2559.1994.tb01324.x","article-title":"c-erbB-3 protein expression in human breast cancer: comparison with other tumour variables and survival","volume":"25","author":"CM Quinn","year":"1994","journal-title":"Histopathology"},{"issue":"9","key":"ref66","doi-asserted-by":"crossref","first-page":"e0138336","DOI":"10.1371\/journal.pone.0138336","article-title":"ERBB3 Positively Correlates with Intestinal Stem Cell Markers but Marks a Distinct Non Proliferative Cell Population in Colorectal Cancer","volume":"10","author":"T Jarde","year":"2015","journal-title":"PloS one"},{"issue":"5","key":"ref67","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1136\/jclinpath-2014-202657","article-title":"Protein expression of HER2, 3, 4 in gastric cancer: correlation with clinical features and survival","volume":"68","author":"XX He","year":"2015","journal-title":"Journal of clinical pathology"},{"key":"ref68","article-title":"Proficiency testing in immunohistochemistry-experiences from Nordic Immunohistochemical Quality Control (NordiQC)","author":"M Vyberg","year":"2015","journal-title":"Virchows Archiv: an international journal of pathology"},{"issue":"5","key":"ref69","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1111\/apm.12359","article-title":"Targeted therapy in gastric cancer","volume":"123","author":"A Thiel","year":"2015","journal-title":"APMIS: acta pathologica, microbiologica, et immunologica Scandinavica"},{"issue":"8","key":"ref70","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1002\/cncr.21782","article-title":"Comparison of two antibodies for immunohistochemical evaluation of epidermal growth factor receptor expression in colorectal carcinomas, adenomas, and normal mucosa","volume":"106","author":"R Bhargava","year":"2006","journal-title":"Cancer"},{"issue":"4","key":"ref71","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1158\/1055-9965.EPI-10-0097","article-title":"Analytic variability in immunohistochemistry biomarker studies","volume":"19","author":"VK Anagnostou","year":"2010","journal-title":"Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology"},{"issue":"6","key":"ref72","doi-asserted-by":"crossref","first-page":"691","DOI":"10.5858\/arpa.2011-0168-RS","article-title":"HER2\/neu gene amplification and protein overexpression in gastric and gastroesophageal junction adenocarcinoma: a review of histopathology, diagnostic testing, and clinical implications","volume":"136","author":"JF Hechtman","year":"2012","journal-title":"Archives of pathology & laboratory medicine"},{"issue":"3","key":"ref73","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s00428-010-0952-2","article-title":"HER2 diagnostics in gastric cancer-guideline validation and development of standardized immunohistochemical testing","volume":"457","author":"J Ruschoff","year":"2010","journal-title":"Virchows Arch"},{"issue":"6","key":"ref74","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.1016\/S0002-9440(10)63075-1","article-title":"Tissue microarrays for rapid linking of molecular changes to clinical endpoints","volume":"159","author":"J Torhorst","year":"2001","journal-title":"Am J Pathol"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0148101","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,4]],"date-time":"2019-09-04T08:22:18Z","timestamp":1567585338000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0148101"}},"subtitle":[],"editor":[{"given":"Yves","family":"St-Pierre","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2016,2,4]]},"references-count":74,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2016,2,4]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0148101","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,2,4]]}}}